Neurochem Will Resubmit Kiacta After Conducting New Phase III Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Company pulls NDA for AA amyloidosis therapy, currently "approvable" at FDA, while it conducts a new trial.
You may also be interested in...
Neurochem Drops Phase III Alzheimer’s Disease Candidate, Refocuses Pipeline
Firm will move a tramiprosate pro-drug into preclinical development and launch Alzhemed as a nutraceutical, in line with a new business model.
Neurochem Gets Second FDA “Approvable” Letter For Kiacta
FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.